RLS Radiopharmacies has announced a partnership with Eckert & Ziegler, a global leader in isotope technology, to enhance its production capabilities of gallium-68 (Ga-68)-based radiopharmaceuticals.

This strategic collaboration will see the installation of Eckert & Ziegler's GalliaPharm generators across all 31 of RLS's Joint Commission-accredited radiopharmacies in the U.S., empowering them to produce Ga-68 radiolabeled diagnostics for neuroendocrine tumors and prostate cancer.

Gallium-68, a critical component in PET imaging, has a short half-life, which necessitates its production close to the time of patient dosing, a logistical challenge that RLS aims to overcome with this partnership.

RLS CEO Stephen Belcher emphasized the significance of this advancement, stating, “To help meet the ever-increasing demand for precision diagnostics in cancer treatment, we are collaborating with Eckert & Ziegler to place advanced Ga-68 radiolabeling technology into the hands of all our skilled radiopharmacists nationwide."

The generators provided by Eckert & Ziegler offer a cost-effective and flexible solution for the production of Ga-68, compared to traditional methods requiring significant investment in large-scale equipment. The technology enables the low-cost radiolabeling of biomolecules for PET imaging.